This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Levodopa and dopamine decarboxylase inhibitors

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Levo-DOPA (L-DOPA) is a precursor of dopamine. Dopamine itself does not cross the blood-brain barrier and so is not effective as a drug. L-DOPA does enter the brain and is converted to dopamine in the striatum.

L-DOPA is usually given in conjunction with an inhibitor of dopamine decarboxylase. The inhibitor does not cross the blood-brain barrier hence the side-effects of peripheral dopamine production, such as nausea, are reduced while the central actions of L-DOPA are augmented.

NICE states that it is not possible to identify a universal first-choice drug therapy for people with early Parkinson's disease (PD). A possible initial first-choice therapy is levodopa therapy (2)

  • the dose of levodopa should be kept as low as possible to maintain good function in order to reduce the development of motor complications
  • modified-release levodopa preparations may be used to reduce motor complications in people with later PD, but should not be drugs of first choice

Levodopa, with a peripheral inhibitor of the aromatic L-amino acid decarboxylase such as carbidopa, is the most effective symptomatic treatment for PD; however, as PD progresses, oral medication inadequately controls symptoms due to an increasingly narrowing therapeutic window (3).

Foslevodopa/foscarbidopa, is a formulation of LD/CD phosphate prodrugs (3)

  • by generating prodrugs of levodopa and carbidopa the solubility is increased by > 100-fold which allows for a highly concentrated foslevodopa/foscarbidopa solution and enables its administration through a minimally invasive subcutaneous (SC) infusion
  • upon delivery to the body, foslevodopa/foscarbidopa is quickly and almost completely metabolized to levodopa/carbidopa by alkaline phosphatases
  • continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa alone can achieve high sustained and steady-state therapeutic levels of plasma

Reference:

  1. Clarke CE (1999). Managing early Parkinson's disease. The Practitioner; 243: 39-47.
  2. NICE (June 2006). Parkinson's disease
  3. Rosebraugh M, Liu W, Neenan M, Facheris MF. Foslevodopa/Foscarbidopa Is Well Tolerated and Maintains Stable Levodopa and Carbidopa Exposure Following Subcutaneous Infusion. J Parkinsons Dis. 2021;11(4):1695-1702.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.